Website Under Construction!
“Creating the world’s most robust mitochondrial drug platform to treat common and rare metabolic diseases.”
Symmetry Therapeutics, Inc. is an early-stage biotech company creating the world’s most robust mitochondrial carrier drug platform to treat common and rare metabolic diseases. Metabolic diseases range from highly prevalent chronic diseases with serious health consequences (e.g. obesity, type 2 diabetes) to rare, fatal inborn errors of metabolism with few or no therapeutic options (e.g. glycogen storage diseases, maple syrup urine disease). Targeting metabolite carrier proteins is an untapped strategy to treat a wide variety of metabolic diseases by inducing mitochondrial biogenesis and improving mitochondrial health. However, such therapies do not exist and are urgently needed to tackle some of society’s most pressing medical problems. That's why we started Symmetry Therapeutics. And that's why we are translating our patented scientific advances into meaningful therapeutic options for patients.